Results 221 to 230 of about 195,376 (282)

A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma

open access: yesIJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Cytokine release syndrome (CRS) is a rare immune‐related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab–axitinib therapy for renal cell carcinoma (RCC) has yet to be reported. Differentiating early CRS from an infusion‐related reaction (IRR) is clinically challenging, particularly ...
Rio Shibata   +7 more
wiley   +1 more source

Differential Regulation of Wingless-Wnt/c-Jun N-Terminal Kinase Crosstalk via Oxidative Eustress in Primary and Metastatic Colorectal Cancer Cells. [PDF]

open access: yesBiomedicines
Aceto GM   +9 more
europepmc   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

open access: yesMedicinal Research Reviews, Volume 46, Issue 2, Page 475-512, March 2026.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova   +3 more
wiley   +1 more source

RNA‐Binding Proteins and Ferroptosis in Cancer: Mechanism and Therapeutic Implications

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Ferroptosis critically influences cancer cell fate and represents a promising therapeutic strategy. Emerging evidence identifies RNA‐binding proteins (RBPs) as key post‐transcriptional regulators of ferroptosis. The figure summarizes ferroptosis‐related RBPs across cancers: blue RBPs act as tumor suppressors by promoting ferroptosis, whereas red RBPs ...
Linlin Chang   +6 more
wiley   +1 more source

Identification of potent schistosomicidal compounds predicted as type II-kinase inhibitors against Schistosoma mansoni c-Jun N-terminal kinase SMJNK. [PDF]

open access: yesFront Parasitol
Moreira BP   +9 more
europepmc   +1 more source

Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans

open access: yesJournal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.
ABSTRACT Background and Aims Bortezomib‐induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets.
Nadine Cebulla   +18 more
wiley   +1 more source

Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c‑Jun N‑Terminal Kinase 3

open access: yesACS Omega, 2018
Francesco Ansideri   +11 more
doaj   +1 more source

Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway. [PDF]

open access: yesCell Death Discov
Taylor RN   +8 more
europepmc   +1 more source

A novel single‐cell NAD‐ME C4 subtype integrated with CAM and bicarbonate use in an aquatic plant

open access: yesNew Phytologist, Volume 249, Issue 5, Page 2386-2401, March 2026.
Summary Many plants maximize photosynthesis by using a CO2‐concentrating mechanism (CCM). Based on physiology, the freshwater plant Ottelia alismoides has three CCMs: C4 metabolism (NAD‐malic enzyme (NAD‐ME) subtype) and bicarbonate‐use during the day plus crassulacean acid metabolism (CAM) at night and lacks Kranz anatomy. Here, we combined a range of
Hong Sheng Jiang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy